



Biocon Limited
20th KM Hosur Road
Electronics City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423
CIN : L24234KA1978PLC003417

February 27, 2020

www.biocon.com

To The Manager BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code- 532523	To The Manager, National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050 Scrip Symbol- Biocon
--	--

Dear Sir/Madam,

Subject: Company Statement - Biocon's Small Molecules API Manufacturing Facility Completes Post-Approval and GMP U.S. FDA Inspection

Please find below the "Company Statement" on the subject matter.

"This is to inform you that the U.S. Food and Drug Administration (FDA) conducted a Post-Approval and GMP inspection of our Small Molecules API Manufacturing Facility at 20th KM, Biocon Campus, Bengaluru, between Feb 20 and Feb 26, 2020.

At the conclusion of the inspection the agency issued a Form 483, with two observations, which are procedural in nature. We are confident of addressing these observations expeditiously and will respond to the FDA with a Corrective and Preventive Action Plan (CAPA) in a timely manner.

*We remain committed to global standards of Quality and Compliance." - **Company Spokesperson***

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

Memel.



Mayank Verma
Company Secretary & Compliance Officer